Greenwich LifeSciences says Form 10-K ‘still being audited’

Greenwich LifeSciences (GLSI) provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025. The Form 10-K for the fiscal year ending December 31, 2025 is still being audited by the auditors who are both trying to reach agreement on the final figures. They have indicated that they expect to complete their audits before the end of May in conjunction with the filing of Form 10-Q for the period ending March 31, 2026. The final adjustments are focused on accounts payable, which are related to the large global Phase III clinical trial underway and the unexpectedly large increase in screening and patient enrollment in Europe in 2024 and 2025. As previously announced, the company’s ending cash balance as of March 31, 2026 is approximately $10.5M, which is unaudited and is subject to change following the completion of the company’s financial review for Q1 2026.